Radiopharm Theranostics Reports 92% Success Rate for RAD 101 in Phase 2b Brain Metastases Trial
I'm PortAI, I can summarize articles.
Radiopharm Theranostics Ltd. announced interim results from its U.S. Phase 2b clinical imaging trial of RAD 101 in patients with brain metastases. The trial showed a 92% success rate, with 11 out of 12 patients achieving concordance with MRI imaging. RAD 101 targets fatty acid synthase (FASN) and is radiolabelled with Fluorine-18. The company plans to initiate a pivotal study by the end of 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments